Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00370500
Status:
COMPLETED
Last Update Posted:
2020-12-14
First Post:
2006-08-30
Brief Title:
Quetiapine and the Dopaminergic Epigenetic Control
Sponsor:
University of Erlangen-Nürnberg Medical School
Organization:
University of Erlangen-Nürnberg Medical School
Study Overview
Official Title:
Quetiapine and the Dopaminergic Epigenetic Control - a Pilot Study
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BACKGROUND
Epigenetic modifications such as DNA-methylation and histone acetylation are known to be involved in the pathophysiology of schizophrenia Aim of the present study is to investigate
1 whether differences in the methylation pattern of the promoters of dopaminergic genes exist between schizophrenic patients and healthy controls and
2 whether treatment with the second generation antipsychotic quetiapine leads to changes in the methylation pattern of those genes in patients suffering from schizophrenia
STUDY DESIGN AND METHODS
50 male patients and 50 male controls are to be enrolled into the study Patients will be treated with quetiapine for 3 weeks Blood samples will be drawn before treatment and after three weeks to measure DNA-methylation status Clinical characterisation includes PANSS AIMS BDI Healthy probands will not be treated
Epigenetic modifications such as DNA-methylation and histone acetylation are known to be involved in the pathophysiology of schizophrenia Aim of the present study is to investigate
1 whether differences in the methylation pattern of the promoters of dopaminergic genes exist between schizophrenic patients and healthy controls and
2 whether treatment with the second generation antipsychotic quetiapine leads to changes in the methylation pattern of those genes in patients suffering from schizophrenia
STUDY DESIGN AND METHODS
50 male patients and 50 male controls are to be enrolled into the study Patients will be treated with quetiapine for 3 weeks Blood samples will be drawn before treatment and after three weeks to measure DNA-methylation status Clinical characterisation includes PANSS AIMS BDI Healthy probands will not be treated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT-Nr 2005-006151-20 | None | None | None |